A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
Conclusions Combination trastuzumab, lapatinib, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with advanced malignancy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Avastin | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Ductal Carcinoma | HER2 | Herceptin | Hypertension | Investigational New Drugs